Isotope peptide fragment for detecting p-Tau217 or fragment thereof, detection method, kit and application
By using isotope-labeled peptides for p-Tau 217 protein detection in Alzheimer's diagnosis, the detection process is simplified, the problem of complex detection and low precision in the prior art is solved, and high sensitivity and high precision are achieved Early diagnosis and course monitoring of disease.
Patent Information
- Application Number
- CN202411207820.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-26
AI Technical Summary
The existing Alzheimer's disease diagnosis methods have problems such as complex detection, long time-consuming, low sensitivity and poor precision, especially in early diagnosis, which makes it difficult to accurately predict and monitor the condition.
Using peptides containing specific isotope labeled peptides for detection of p-Tau 217 protein or its fragments, simplifying the process, monitoring interference and losses during extraction, and improving the accuracy of detection and credibility.
Accurate quantification detection of p-Tau 217 protein is achieved, simplified the detection steps, reduced sample size requirements, improved the sensitivity and precision of the detection, and is suitable for early diagnosis and course monitoring of Alzheimer's disease.
Smart Images

Figure CN119019508A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of protein spectrum detection, and in particular to an isotope peptide segment for detecting p-Tau 217 or a fragment thereof, a detection method, a kit and an application thereof. Background Art
[0002] Alzheimer's Disease (AD), also known as primary senile dementia, is a fatal neurodegenerative disease and the most common type of dementia, accounting for about 50%-70% of dementia cases. The main symptoms are memory loss, cognitive decline, behavioral decline, and decreased ability to live. It may also cause multiple complications such as depression and anxiety, which are very harmful. Like other central nervous system (CNS) degenerative diseases, AD is characterized by disrupted protein production, accumulation, and clearance. In AD, metabolic disorders of the protein amyloid-β (Aβ) are manifested as a large accumulation of this protein in the form of amyloid plaques in the brains of patients with the disease. In addition, the protein Tau accumulates in the brain in the form of Tau tangles. AD leads to memory loss, loss of cognitive function, and ultimately loss of autonomy, and death. The disease causes heavy personal and economic losses to patients, families, and society. Due to the severity and increasing prevalence of this disease in the population, there is an urgent need to develop better diagnosis and treatment.
[0003] At present, the main diagnostic methods for AD are neuropsychological scales, imaging examinations, biomarker detection, etc. Neuropsychological scale assessments have large fluctuations in test results due to differences in the subjects' education level and personal understanding ability; neuroimaging tests mainly include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), etc., which are also strong evidence for AD diagnosis. CT can directly show brain atrophy in AD patients, but its value is limited due to poor soft tissue resolution. MRI and PET are expensive and not suitable for population screening.
[0004] Cerebrospinal fluid (CSF) biomarkers are currently recognized as a source of AD markers. CSF examinations can be used to rule out rare, reversible cognitive impairment diseases and can also help with active molecular diagnosis of AD. However, CSF isolation and invasive procedures limit the use of these biomarkers in the diagnosis of early AD. Currently, research on blood biomarkers involved in the pathogenesis of AD involves multiple markers, including Aβ, Tau protein, p-Tau protein, etc. These biomarkers can also be measured faster and less frequently in plasma, and can provide an important basis for the early diagnosis of Alzheimer's disease.
[0005] For example, US2016238619Al discloses a method of 13C6 leucine-labeled Tau was used as a quantitative standard and was incorporated into a standard curve containing samples of Tau with a concentration range of 5 ng / ml to 5l pg / ml. In addition, the quantitative standard was incorporated into CSF from two different individuals. Tau was isolated from the sample using immunoprecipitation, then digested with trypsin and analyzed by mass spectrometry. The ratio of unlabeled Tau to the quantitative standard was calculated for all samples, and a standard curve was generated. The standard curve was linear within the test range (5 ng / mL to 5 pg / mL) and was used to calculate the concentration of Tau in the CSF sample. The concentration of Tau in the CSF sample was about 1.2 ng / mL, and the CV of the triplicate measurements of the Tau concentration was 4% for one CSF sample and 7% for another CSF sample. This illustrates the feasibility of using stable isotope-labeled Tau protein as a quantitative standard and associating the ratio of unlabeled to labeled Tau with a standard curve to allow measurement of the concentration of Tau in an unknown sample. However, there is no report on the quantitative detection method of p-Tau 217 protein using stable isotope-labeled peptides. Summary of the invention
[0006] In view of this, the main purpose of the present invention is to provide an isotope peptide segment, a detection method, a kit and an application for detecting p-Tau 217 or its fragments, in order to at least partially solve the above technical problems.
[0007] In order to achieve the above-mentioned object, as a first aspect of the present invention, an isotope peptide segment comprising an amino acid sequence as shown in SeqNo.1 is provided: X-TPGSRSRTPSLP T PPT R EPKKVAV-X, X is any amino acid, wherein the amino acid T at position 13 (see bold and underlined) on the peptide is phosphorylated, and all the carbon atoms of the amino acid R at position 17 (see bold and underlined) are isotopically labeled. 13 C labeling, all N atoms of the amino acid R at position 17 (see bold and underlined) are isotopically 15N labeling. Due to the accidental errors caused by human operations (such as pipetting) during protein extraction, on the other hand, the entire protein extraction process involves steps such as immunoprecipitation, washing, digestion, desalting, reconstruction, and mass spectrometry detection, there will be certain losses and signal fluctuations, resulting in poor repeatability of the detection results of the target protein. Since the physicochemical properties of the extended isotope peptide segment are consistent with those of the target protein, its behavior during sample extraction and mass spectrometry detection is also consistent. Adding an isotope peptide segment of known concentration before sample processing can, on the one hand, monitor the loss and fluctuation of the target protein during the extraction process, and can also correct the loss and fluctuation; on the other hand, since the isotope peptide segment of the same concentration and the target peptide segment (the specific peptide segment produced after the target protein is digested) have the same signal on the mass spectrometer, the isotope peptide segment can be used for the quantification of the target protein.
[0008] As a second aspect of the present invention, the present invention provides a method for detecting p-Tau 217 protein or a fragment thereof, the detection method comprising the step of adding the isotope peptide fragment as described in the first aspect during sample pretreatment.
[0009] Preferably, the detection method comprises the following steps:
[0010] 1) Sample pretreatment: adding the isotope peptide fragment to the sample, and then adding the sample diluent and mixing to obtain solution A;
[0011] 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate, and pass through a magnetic rack to obtain a purified immune-enriched complex;
[0012] 3) Washing: The immune-enriched complexes were washed with NP40 PBS to obtain washed complexes;
[0013] 4) Digestion: Add NH4HCO3 to the washed complex for solvent replacement and redissolution, and then digest and terminate;
[0014] 5) Desalting, vacuum concentration and mass spectrometry injection;
[0015] 6) Perform detection using mass spectrometry and output the results.
[0016] Preferably, the isotope peptide segment in step 1) comprises: an aqueous solution of the isotope peptide segment having the amino acid sequence shown in Seq No.1.
[0017] Preferably, the sample diluent in step 1) comprises: Tris-HCl, NaCl, EDTA (ethylenediaminetetraethylene glycol acid), protease inhibitors and phosphatase inhibitors; and / or
[0018] In step 1), the sample diluent further comprises NP 40 and / or Tween 20;
[0019] Preferably, the sample diluent in step 1) comprises: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA (ethylenediaminetetraethylene glycol acid), 0.02%-0.2% protease inhibitor by mass fraction and 0.02%-0.2% phosphatase inhibitor by mass fraction; wherein the concentration of Tris-HCl can be 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM M, 75mM or all values within the range, which are not listed one by one due to space limitations; the concentration of NaCl can be 30mM, 35mM, 40mM, 45mM, 50mM, 55mM, 60mM, 65mM, 70mM, 75mM or all values within the range, which are not listed one by one due to space limitations; the concentration of EDTA can be 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM or all values within the range, which are not listed one by one due to space limitations. The role of the sample diluent: reduce the viscosity of plasma, make the antibody microspheres evenly distributed in the plasma, and increase the capture probability of the target protein; create a buffer system and the presence of non-ionic surfactants, which are conducive to the binding of antigens and antibodies and reduce the nonspecific adsorption of microspheres to non-target proteins; since blood contains a series of biologically active enzymes, it can enzymatically hydrolyze proteins in vitro, and the addition of protease inhibitors and phosphatase inhibitors can inhibit the enzymatic hydrolysis of target proteins by biologically active enzymes.
[0020] And / or the sample diluent in step 1) further comprises 0.1%-1% by mass of NP40 and / or Tween 20 (polyether sulfate nonionic surfactant);
[0021] Preferably, the sample is a CSF, blood or plasma sample.
[0022] Preferably, step 2) comprises: adding the nanomagnetic microsphere-antibody complex to solution A, incubating with rotation at room temperature for at least 2 hours, and passing through a magnetic rack to obtain a purified immune-enriched complex (i.e., a target protein-antibody-microsphere complex);
[0023] The antibody-microsphere complex has a monoclonal antibody for recognizing the p-Tau 217 site, and its purpose is to capture the target protein (p-Tau 217) in plasma to obtain an immune-enriched complex (i.e., the target protein-nanomagnetic microsphere-antibody complex). Since the nanomagnetic superparamagnetic microspheres are easy to demagnetize, they are helpful for subsequent separation and efficient washing. Even after multiple magnetizations, the performance of the superparamagnetic nanomicrospheres remains unchanged, and the repeatability is good. Since the magnetic frame has a built-in magnet, the magnetic nanomagnetic microsphere-antibody complex can be fixed on the container wall to achieve solid-liquid separation, which is conducive to automated conversion. By combining it with specific antibodies, the solution and the nanomagnetic-antibody microsphere complex can be separated without centrifugation, thereby achieving the effect of simplifying the process.
[0024] Preferably, step 3) comprises: washing the immuno-enriched complex with a PBS solution containing 0.1% to 0.5% NP40 by mass for at least three times. The role of the nonionic surfactant is to remove the nonspecific adsorption on the surface of the nanomagnetic microsphere-antibody complex. The mass fraction of the PBS solution of NP40 can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45% or all values within the range, which are not listed one by one due to space limitations.
[0025] Preferably, step 4) comprises: washing the washed complex with NH4HCO3 digestion solution, replacing the solution, then adding NH4HCO3 to re-dissolve, then adding trypsin to shake digest, and adding formic acid aqueous solution to terminate;
[0026] Among them, the main function of ammonium bicarbonate (NH4HCO3) is to provide an alkaline hydrolysis environment to ensure the highest activity of trypsin (optimal pH 8-9), and decompose the p-Tau 217 protein into specific peptides that can be used for mass spectrometry detection. The concentration of NH4HCO3 can be 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 110mM, 120mM, 130mM, 140mM, 150mM, 160mM, 170mM, 180mM, 190mM or all values within the range, which will not be listed one by one due to space limitations.
[0027] Preferably, the desalination in step 5) comprises:
[0028] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;
[0029] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0030] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0031] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;
[0032] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;
[0033] Preferably, the vacuum concentration and mass spectrometry sampling in step 5) comprises: passing the desalted sample through a vacuum concentration centrifuge and drying;
[0034] Preferably, the mass spectrometry sampling in step 5) comprises: re-dissolving the dried sample with formic acid water, and injecting the sample after oscillation and centrifugation;
[0035] Preferably, the method comprises the following steps:
[0036] 1) Sample pretreatment: adding an isotope internal standard solution and a sample diluent to the sample to obtain a solution A; the isotope internal standard solution comprises: an aqueous solution containing 5-50 fmol / L of an isotope peptide segment of the amino acid sequence shown in Seq No. 1; the sample diluent comprises: 0.1%-1% NP40 by mass, 0.1%-1% Tween 20 by mass, 20-80 mM Tris-HCl, 30-80 mM NaCl, 0.02%-0.2% protease inhibitor by mass, and 0.02%-0.2% phosphatase inhibitor by mass; the sample is a CSF, blood or plasma sample;
[0037] 2) Immunoenrichment: Add the antibody-microsphere complex to solution A and incubate at room temperature for at least 2 hours. Then place the container (EP tube) on a magnetic rack and let it stand until the protein-antibody-microsphere complex is adsorbed to the tube wall. Remove the supernatant to obtain the purified immune-enriched complex.
[0038] 3) Washing: Wash the immuno-enriched complexes at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass to obtain washed complexes;
[0039] 4) Digestion: Add 20-200 mM NH4HCO3 to the washed complex for solvent replacement and redissolution, then add trypsin for oscillation digestion for at least 8 h, and terminate by adding 10% by mass formic acid aqueous solution;
[0040] 5) Desalination:
[0041] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;
[0042] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0043] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0044] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;
[0045] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;
[0046] 6) Dry the desalted sample using a vacuum concentrator centrifuge, re-dissolve the dried sample in 0.1% formic acid water, shake and centrifuge, and then inject;
[0047] 7) Use orbital ion trap mass spectrometry to detect and output the results.
[0048] The principle of the present invention is as follows: the present invention specifically adsorbs the target protein and isotope peptide fragment (i.e., p-Tau 217 protein or a p-Tau217 protein fragment that can be specifically recognized by an antibody) in the sample on the antibody-microsphere complex by immunoenrichment, while the capture ability of other target proteins is weak, and the microspheres are uniform in size, monodisperse and non-porous, and there is almost no non-specific adsorption of sugars, lipids, and non-target proteins of the biological matrix, which effectively improves the enrichment of the target protein and reduces the loss during the cleaning process. Since the nanomagnetic microspheres have superparamagnetism, the complex after immunoenrichment is placed on a magnetic frame with a magnetic field, and the nanomagnetic microsphere-antibody complex adsorbed with the target protein can be adsorbed, and other impurities that cannot be absorbed by the immune microspheres cannot remain in the magnetic field, so they can be washed and removed; after thorough cleaning, the adsorbed antigen-antibody is digested with trypsin to separate them (the antibody binds to the nanomagnetic microspheres and continues to remain in the magnetic field, while the target protein is released); subsequently, after termination, desalting, drying, centrifugation and other steps, the target protein is thoroughly purified and separated. Principle of mass spectrometry detection and internal standard quantification: The target protein or target peptide and the stable isotope-labeled peptide have the same physical or chemical properties. Except for slightly different masses, their extraction efficiency during the extraction process and the way they are fragmented by collision in the mass spectrometer are the same. Therefore, the signal fluctuations caused by the influence of the matrix during the extraction process and the mass spectrometry detection process can be effectively monitored and corrected. In addition, since the mass spectrometry signal is proportional to the content of the detected object, the content of the target peptide in the sample can be calculated by the signal of the stable isotope-labeled peptide with an accurate content in the mass spectrometer, and the content of the target protein in the sample can be further calculated. Therefore, using the technology provided herein, endogenous target proteins and their fragments can be quantitatively detected and can be used to diagnose and / or treat subjects suffering from neurological or neurodegenerative diseases or at risk of suffering from neurological or neurodegenerative diseases.
[0049] It should be noted that the raw data output by the orbital ion trap mass spectrometer needs to be imported into the skyline software for secondary processing before the mass spectrometry signal data can be converted into content results.
[0050] As a third aspect of the present invention, the present invention provides a detection kit for p-Tau 217 protein, the kit comprising:
[0051] 1) Pretreatment module: including isotope peptides and sample diluent as shown in Seq No. 1, wherein the formula sample of the isotope peptides is: 5-50fmol / L aqueous solution; the diluent includes: NP40 with a mass fraction of 0.1%-1%, Tween 20 with a mass fraction of 0.1%-1%, Tris-HCl with a concentration of 20-80mM, NaCl with a concentration of 30-80mM, protease inhibitors with a mass fraction of 0.02%-0.2%, and phosphatase inhibitors with a mass fraction of 0.02%-0.2%;
[0052] 2) Immune enrichment module: at least including nanomagnetic microsphere-antibody complex;
[0053] 3) Cleaning the digestion module: at least a PBS solution containing 0.1% to 0.5% NP40 by mass and a 20-200 mM NH4HCO3 solution;
[0054] 4) Desalination module: at least including methanol, 80% by mass acetonitrile aqueous solution, 1% by mass formic acid aqueous solution, and 80% by mass acetonitrile aqueous solution;
[0055] 5) Drying and sampling module: at least 0.1% by mass of formic acid water.
[0056] As a fourth aspect of the present invention, the present invention provides use of the detection kit for p-Tau 217 protein as described in the third aspect in the early diagnosis of Alzheimer's disease.
[0057] Based on the above technical solutions, it can be seen that the isotope peptides, detection methods, kits and applications for detecting p-Tau217 or its fragments of the present invention have at least one of the following beneficial effects compared to the prior art:
[0058] The present invention adds a specific peptide segment labeled with a stable isotope during pretreatment, which can be used for accurate quantification of p-Tau217 protein or its fragments, especially adding it before pretreatment, and monitoring the interference and loss in the p-Tau 217 extraction process throughout the whole process and calibrating it.
[0059] In addition, the detection method of phosphorylated Tau-217 protein or its fragments provided by the present invention has simple steps, short detection time, high sensitivity, good precision, and high credibility of the detection results. Only 5 steps are required to complete the mass spectrometry detection pretreatment, and the required sample amount is reduced by about 75%. The cleaning step is simplified, and the acid precipitation, acid cleaning and solid phase extraction steps in the prior art are omitted, and the digestion incubation time is greatly shortened.
[0060] The present invention solves the problems of the existing Alzheimer's disease detection kits, such as complex operation, long time consumption, low sensitivity, poor precision, lack of accurate prediction ability for Alzheimer's disease, etc., and has important application value and significance. The Alzheimer's disease detection marker p-Tau 217 detection kit provided by the present invention can be used to detect the content of p-Tau 217 in blood samples, and can be used for AD mild cognitive impairment (AD MCI) detection or diagnosis, and / or AD detection or diagnosis, and / or AD course monitoring, and / or AD efficacy evaluation, and / or AD prognosis evaluation, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 is a flow chart for detecting the p-Tau 217 protein or its fragments of the present invention;
[0062] Figure 2 is a comparison chart of p-Tau217 content in plasma of AD and normal subjects in Example 2;
[0063] Figure 3 is the p-Tau217 protein calibration curve of Comparative Example 1;
[0064] Figure 4 This is the p-Tau217 protein calibration curve of Comparative Example 2. DETAILED DESCRIPTION
[0065] The prior art mass spectrometry detection of markers of Alzheimer's disease has complicated pre-processing steps, complex operating procedures, long time consumption and low sensitivity. The inventors of the present invention have studied and simplified and optimized the above steps, so that a higher detection accuracy and detection limit can be achieved through simpler operations.
[0066] Specifically, in the first aspect, the present invention discloses an isotope peptide segment comprising an amino acid sequence as shown in Seq No. 1: X-TPGSRSRTPSLP T PPT R EPKKVAV-X, X is any amino acid, wherein the amino acid T at position 13 (see bold and underlined) on the peptide is phosphorylated, and all the carbon atoms of the amino acid R at position 17 (see bold and underlined) are isotopically labeled. 13 C labeling, all N atoms of the amino acid R at position 17 (see bold and underlined) are isotopically 15 N mark.
[0067] In a second aspect, the present invention provides a method for detecting p-Tau 217 protein or a fragment thereof, the detection method comprising the step of adding the isotope peptide fragment as described in the first aspect during sample pretreatment.
[0068] In a preferred embodiment, the detection method comprises the following steps:
[0069] 1) Sample pretreatment: adding the isotope peptide fragment to the sample, and then adding the sample diluent and mixing to obtain solution A;
[0070] 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate, and pass through a magnetic rack to obtain a purified immune-enriched complex;
[0071] 3) Washing: The immune-enriched complexes were washed with NP40 PBS to obtain washed complexes;
[0072] 4) Digestion: Add NH4HCO3 to the washed complex for solvent replacement and redissolution, and then digest and terminate;
[0073] 5) Desalting, vacuum concentration and mass spectrometry injection;
[0074] 6) Perform detection using mass spectrometry and output the results.
[0075] In a preferred embodiment, the isotope peptide segment in step 1) comprises: an aqueous solution of the isotope peptide segment having the amino acid sequence shown in Seq No.1.
[0076] In a preferred embodiment, the sample diluent in step 1) comprises: Tris-HCl, NaCl, EDTA (ethylenediaminetetraethylene glycol acid), protease inhibitors and phosphatase inhibitors; and / or
[0077] The sample diluent in step 1) further comprises NP40 and / or Tween 20;
[0078] In a preferred embodiment, the sample diluent in step 1) comprises: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA (ethylenediaminetetraethylene glycol acid), calculated by mass fraction: 0.02%-0.2% protease inhibitor and 0.02%-0.2% phosphatase inhibitor; wherein the concentration of Tris-HCl can be 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM or all values within the range, which are not listed one by one due to space limitations. For example; the concentration of NaCl can be 30mM, 35mM, 40mM, 45mM, 50mM, 55mM, 60mM, 65mM, 70mM, 75mM or all values within the range, which are not listed one by one due to space limitations; the concentration of EDTA can be 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM or all values within the range, which are not listed one by one due to space limitations.
[0079] And / or the sample diluent in step 1) further comprises NP40 and / or Tween 20 (polyether sulfate nonionic surfactant) with a mass fraction of 0.1%-1%;
[0080] In a preferred embodiment, the sample is a CSF, blood or plasma sample.
[0081] In a preferred embodiment, step 2) comprises: adding the nanomagnetic microsphere-antibody complex to solution A, incubating with rotation at room temperature for at least 2 hours, and passing through a magnetic rack to obtain a purified immune-enriched complex (i.e., the target protein-antibody-microsphere complex).
[0082] In a preferred embodiment, step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution of NP40 having a mass fraction of 0.1%-0.5%. The mass fraction of the PBS solution of NP40 can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45% or all values within the range, which are not listed one by one due to space limitations.
[0083] In a preferred embodiment, step 4) comprises: washing the washed complex with NH4HCO3 digestion solution, replacing the solution, then adding NH4HCO3 to dissolve it again, adding trypsin to shake and digest it, and adding formic acid aqueous solution to terminate it; the concentration of NH4HCO3 can be 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 110mM, 120mM, 130mM, 140mM, 150mM, 160mM, 170mM, 180mM, 190mM or all values within the range, which are not listed one by one due to space limitations.
[0084] In a preferred embodiment, the desalination in step 5) comprises:
[0085] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;
[0086] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0087] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0088] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;
[0089] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;
[0090] In a preferred embodiment, the vacuum concentration and mass spectrometry injection in step 5) comprises: passing the desalted sample through a vacuum concentration centrifuge and drying;
[0091] In a preferred embodiment, the mass spectrometry injection in step 5) comprises: re-dissolving the dried sample with formic acid water, and injecting the sample after oscillation and centrifugation;
[0092] In a preferred embodiment, the method comprises the following steps:
[0093] 1) Sample pretreatment: adding an isotope internal standard solution and a sample diluent to the sample to obtain a solution A; the isotope internal standard solution comprises: an aqueous solution containing 5-50 fmol / L of an isotope peptide segment of the amino acid sequence shown in Seq No. 1; the sample diluent comprises: 0.1%-1% NP40 by mass, 0.1%-1% Tween 20 by mass, 20-80 mM Tris-HCl, 30-80 mM NaCl, 0.02%-0.2% protease inhibitor by mass, and 0.02%-0.2% phosphatase inhibitor by mass; the sample is a CSF, blood or plasma sample;
[0094] 2) Immunoenrichment: Add the antibody-microsphere complex to solution A and incubate at room temperature for at least 2 hours. Then place the container (EP tube) on a magnetic rack and let it stand until the protein-antibody-microsphere complex is adsorbed to the tube wall. Remove the supernatant to obtain the purified immune-enriched complex.
[0095] 3) Washing: Wash the immuno-enriched complexes at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass to obtain washed complexes;
[0096] 4) Digestion: Add 20mM-200mM NH4HCO3 to the washed complex for solvent replacement and redissolution, then add trypsin for oscillation digestion for at least 8h, and terminate by adding 10% by mass formic acid aqueous solution;
[0097] 5) Desalination:
[0098] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;
[0099] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0100] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0101] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;
[0102] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;
[0103] 6) Dry the desalted sample using a vacuum concentrator centrifuge, re-dissolve the dried sample in 0.1% formic acid water, shake and centrifuge, and then inject;
[0104] 7) Use orbital ion trap mass spectrometry to detect and output the results.
[0105] It should be noted that the raw data output by the orbital ion trap mass spectrometer needs to be imported into the skyline software for secondary processing before the mass spectrometry signal data can be converted into content results.
[0106] In a third aspect, the present invention provides a detection kit for p-Tau 217 protein, the kit comprising:
[0107] 1) Pretreatment module: including isotope peptides and sample diluent as shown in Seq No. 1, wherein the formula sample of the isotope peptides is: 5-50fmol / L aqueous solution; the diluent includes: NP40 with a mass fraction of 0.1%-1%, Tween 20 with a mass fraction of 0.1%-1%, Tris-HCl with a concentration of 20mM-80mM, NaCl with a concentration of 30mM-80mM, protease inhibitors with a mass fraction of 0.02%-0.2%, and phosphatase inhibitors with a mass fraction of 0.02%-0.2%;
[0108] 2) Immune enrichment module: at least including nanomagnetic microsphere-antibody complex;
[0109] 3) Cleaning the digestion module: at least a PBS solution containing 0.1% to 0.5% NP40 by mass and a 20 mM to 200 mM NH4HCO3 solution;
[0110] 4) Desalination module: at least including methanol, 80% by mass acetonitrile aqueous solution, 1% by mass formic acid aqueous solution, and 80% by mass acetonitrile aqueous solution;
[0111] 5) Drying and sampling module: at least 0.1% by mass of formic acid water.
[0112] In a fourth aspect, the present invention provides use of the detection kit for p-Tau 217 protein as described in the third aspect in the early diagnosis of Alzheimer's disease.
[0113] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.
[0114] Collection of plasma samples: Peripheral blood from Alzheimer's disease patients and healthy subjects was collected from the blood bank of a municipal hospital in Anhui Province. After plasma was extracted from each peripheral blood sample, it was stored at -80℃ for future use.
[0115] Example 1
[0116] This embodiment is a detection kit for Alzheimer's biomarker (p-Tau 217) protein or its fragment, comprising:
[0117] 1) Internal standard solution: aqueous solution containing the isotope peptide fragment shown in Seq No.1;
[0118] 2) Pretreatment reagents: 20mM-80mM Tris-HCl, 30mM-80mM NaCl and 1mM-10mM EDTA (ethylenediaminetetraethylene glycolic acid), calculated by mass fraction: 0.1%-1% NP40 or Tween-20, 0.02%-0.2% protease inhibitor and 0.02%-0.2% phosphatase inhibitor.
[0119] 3) Nanomagnetic microsphere-p-Tau 217 protein antibody complex: Take 10 μL of nanomagnetic microsphere suspension (10 mg / mL 0.1% BSA + 0.02% NaN3) and place it in a 1.5 mL EP tube. Wash it three times with 2 mM EDTA in PBS solution by rotation, 3 min / time, 1 mL / time. After removing the supernatant, add 4 μL p-Tau 217 antibody and 500 μL PBS solution, and incubate it with rotation at 4°C for 8 h to obtain the nanomagnetic microsphere-antibody complex.
[0120] 4) Cleaning solution: 0.1%-0.5% NP40 PBS solution;
[0121] 5) Digestive fluid: 20mM-100mM ammonium bicarbonate (NH4HCO3).
[0122] 6) Reconstitution solution: 0.1% formic acid in water.
[0123] Table 1 Reagent material information corresponding to the kit
[0124]
[0125] Example 2
[0126] This embodiment is a method for detecting p-Tau217 in a blood sample. The kit used is the kit prepared in Example 1, and the supporting detection equipment is a high-resolution mass spectrometer Exploris 480 (Thermofisher Scientific) with an orbital ion trap capable of detecting p-Tau 217 protein.
[0127] 1) Sample pretreatment: add 10 μL of internal standard solution to 1 mL of sample, then add 2 mL of sample diluent, and rotate to mix to obtain solution A;
[0128] 2) Immunoenrichment: Add 10 μL of p-Tau protein antibody-nanomagnetic microsphere complex to solution A, incubate with rotation at room temperature for 2 h, then place the container (EP tube) on the magnetic rack and let it stand for 1 min. After the protein-antibody-microsphere complex is fixed and adsorbed to the tube wall, remove the supernatant and retain the p-Tau protein and isotope-extended peptide-antibody-microsphere complex.
[0129] 3) Washing: The immune-enriched complexes were respectively washed with 3 mL of washing solution at a frequency of 1 mL / time / 5 min by rotation, and the operation was repeated 3 times. The container (EP tube) was placed on a magnetic rack and allowed to stand for 1 min. After the protein-antibody-microsphere complex was fixed and adsorbed to the tube wall, the supernatant was removed to obtain the washed complex;
[0130] 4) Digestion: The washed complex was incubated with a digestion solution at a frequency of 1 mL / time / 5 min by rotation, and the dissolution and replacement operation was repeated 3 times. 100 μL of digestion solution and 1 μL of enzyme were added, and the mixture was shaken for 30 s, ultrasonicated for 30 s, and incubated at 37°C with shaking at 1000 rpm for 8 h. Finally, 10 μL of 10% formic acid aqueous solution was added to terminate the reaction.
[0131] 5) Desalting, vacuum concentration and mass spectrometry injection:
[0132] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;
[0133] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0134] ③ Add 200 μL 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;
[0135] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;
[0136] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;
[0137] The filtrate was placed on a vacuum freeze dryer and centrifuged for 30 min, then 10 μL of the reconstitution solution was added, vortexed for 5 min, and centrifuged for 10 s.
[0138] 6) Perform detection using mass spectrometry and output the results.
[0139] The mass spectrometer parameters were set as follows: Isolation window: 0.7; HCD: 30%; Orbitrap Resolution: 45000; Scan range: 120-1500; RF lens: 50%; AGC: 100%; Maximum injection time: 110. Chromatographic analysis time: 30 min. Injection volume: 5 μL. The chromatographic parameter settings are shown in Table 2.
[0140] Table 2 Chromatographic parameters
[0141]
[0142]
[0143] 7) Result calculation: The peak area of the target peptide is compared with the peak area of the isotope peptide, and then multiplied by the concentration of the isotope peptide to obtain the concentration of the target peptide, and then the concentration of the target peptide is converted into the concentration of the target protein.
[0144] Performance Testing
[0145] (1) Repeatability test: The plasma of healthy subjects and AD patients (diagnosed by PET-CT) was tested separately, and each sample was processed 3 times for 3 consecutive days. The mean and coefficient of variation (CV, %) of the test results of each sample were calculated. The results are shown in Table 3. The intra-day CV was <7%, and the inter-day CV was <6%, both less than 15%, meeting the clinical testing requirements.
[0146] Table 3 Repeatability test
[0147]
[0148] (2) Verification of spike recovery rate: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and 6 portions were prepared in parallel according to the process of the embodiment. According to accuracy = (measured value - background concentration) / theoretical concentration * 100%. The results are shown in Table 4. The low concentration and high concentration spike recovery rates of Example 1 are both above 85%, meeting the clinical quantitative requirements.
[0149] Table 4 Spiked recovery results
[0150]
[0151]
[0152] (3) Clinical application performance evaluation: A sample of patients who sought medical treatment in Chongqing was selected, including 20 patients with Alzheimer's disease and 20 normal subjects. The kit prepared in Example 1 was used for testing. The results are shown in Table 5. Figure 2 This is a comparison of the p-Tau 217 content in the plasma of AD patients and normal people. Figure 2 It can be seen that the content of p-Tau 217 in AD patients and healthy people is different. Figure 2 , indicating that the kit of this embodiment can be used for screening cases of early Alzheimer's disease, and has good application prospects in the diagnosis of early Alzheimer's disease.
[0153] Table 5 Actual sample test results
[0154]
[0155]
[0156] Comparative Example 1
[0157] The difference between Comparative Example 1 and Example 2 is that the isotope peptide fragments shown in Seq No. 1 are not added during sample detection.
[0158] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, and the sample processing and detection were performed according to the sample processing process of Example 4. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa to perform a linear fit. Figure 3 The calibration curve shown in the figure shows that the linear correlation coefficient R 2 =0.9674, indicating that without isotope peptide signal correction, the linearity of p-Tau 217 in the concentration range of 0.1-30pg / mL is poor and cannot meet the clinical quantitative requirements.
[0159] (2) Repeatability test: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing process of Comparative Example 1. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample. The results are shown in Table 6. It can be seen that the precision CV of the low-concentration sample measured in Comparative Example 1 is 19.14%, which is greater than 15% and cannot meet the clinical quantitative requirements.
[0160] Table 6 Precision test results of comparative example 1
[0161]
[0162]
[0163] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were performed according to the operating steps of the kit of the present invention, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 7, and it can be seen that the accuracy of comparative example 1 is <80%, which cannot meet the clinical quantitative requirements.
[0164] Table 7 Accuracy test results of comparative example 1
[0165] serial number Sample 1 Sample 2 Test results after spike 0.23 0.744 Background concentration 0.12 0.12 Accuracy, % 73.33 78.00
[0166] Comparative Example 2
[0167] The difference between Comparative Example 2 and Example 2 is that the isotope peptide segment shown in Seq No. 1 is not added, and the specific peptide segment TPSLP is added before mass spectrometry detection. T PPT R (Among them, the amino acid T at position 6 (see bold and underlined) is phosphorylated, and all C atoms of the amino acid R at position 10 (see bold and underlined) are isotopically labeled. 13 C labeling, all N atoms of amino acid R at position 10 (see bold and underlined) are isotopically 15 N-labeled) reconstitution solution.
[0168] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, which was processed and tested according to the sample processing process of Comparative Example 2. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa for linear fitting. Figure 4 The calibration curve shown in the figure shows that the linear correlation coefficient R 2 =0.9985, indicating that the target protein has good linearity in the concentration range of 0.1 to 30 pg / ml.
[0169] (2) Repeatability determination: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing procedure of Example 1. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample. The results are shown in Table 8. It can be seen that the precision CV of the determination results in Comparative Example 2 was <8%, and its repeatability was lower than that of Example 2.
[0170] Table 8 Precision determination results of comparative example 2
[0171]
[0172] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were carried out according to the treatment process of Comparative Example 2, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 9, and it can be seen that the accuracy of Comparative Example 2 is >80% but <85%, and its effect is lower than that of Example 2.
[0173] Table 9 Accuracy test of comparative example 2
[0174] serial number Sample 1 Sample 2 Test results after spike 0.271 0.739 Background concentration 0.15 0.080 Accuracy, % 80.66 82.38
[0175] In summary, the detection method of phosphorylated p-Tau 217 protein or its fragments provided by the present invention has simple steps, short detection time, high sensitivity, good precision, high credibility of detection results, and only 5 steps are needed to complete the pretreatment of mass spectrometry detection, and the required sample volume is reduced by about 75%, wherein the cleaning step is simplified, the acid precipitation, acid cleaning and solid phase extraction steps in the prior art are omitted, and the digestion incubation time is greatly shortened. In addition, the present invention adds a specific peptide segment labeled with a stable isotope during pretreatment, which can be used for accurate quantification of p-Tau 217 protein or its fragments, especially before pretreatment, and the interference and loss in the extraction process of p-Tau 217 are monitored and calibrated throughout the process.
[0176] The present invention solves the problems of the existing Alzheimer's disease detection kits, such as complex operation, long time consumption, low sensitivity, poor precision, lack of accurate prediction ability for Alzheimer's disease, etc., and has important application value and significance. The Alzheimer's disease detection marker p-Tau 217 detection kit provided by the present invention can be used to detect the content of p-Tau 217 in blood samples, and can be used for AD mild cognitive impairment (AD MCI) detection or diagnosis, and / or AD detection or diagnosis, and / or AD course monitoring, and / or AD efficacy evaluation, and / or AD prognosis evaluation, etc.
[0177] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. An isotopic peptide fragment comprising the amino acid sequence shown in Seq No.
1.
2. A method for detecting p-Tau 217 protein or a fragment thereof, characterized in that: The detection method comprises the step of adding the isotope peptide segment as claimed in claim 1 during sample pretreatment.
3. The detection method according to claim 2, characterized in that: The following steps are involved: 1) Sample pretreatment: adding the isotope peptide fragment to the sample, and then adding the sample diluent and mixing to obtain solution A; 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate, and pass through a magnetic rack to obtain a purified immune-enriched complex; 3) washing: washing the immunoenriched complex with NP40 PBS to obtain a washed complex; 4) Digestion: Add NH4HCO3 to the washed complex for solvent replacement and redissolution, and then digest and terminate; 5) Desalting, vacuum concentration and mass spectrometry injection; 6) Perform detection using mass spectrometry and output the results.
4. The detection method according to claim 3, characterized in that: The sample diluent in step 1) comprises: Tris-HCl, NaCl, EDTA, protease inhibitors and phosphatase inhibitors; and / or The sample diluent in step 1) further comprises NP 40 and / or Tween 20.
5. The detection method according to claim 4, characterized in that: The sample diluent in step 1) comprises: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA, and 0.02%-0.2% by mass of protease inhibitors and 0.02%-0.2% by mass of phosphatase inhibitors; and / or The sample diluent in step 1) further comprises NP40 and / or Tween 20 at a mass fraction of 0.1%-1%.
6. The detection method according to claim 3, characterized in that: Step 2) includes: adding the nanomagnetic microsphere-antibody complex to solution A, incubating with rotation at room temperature for at least 2 hours, and passing through a magnetic rack to obtain a purified immune-enriched complex.
7. The detection method according to claim 3, characterized in that: Step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass.
8. The detection method according to claim 3, characterized in that: Step 4) comprises: washing the washed complex with NH4HCO3 digestion solution, replacing the solution, adding NH4HCO3 to re-dissolve, adding trypsin to shake and digest, and adding formic acid aqueous solution to terminate.
9. A detection kit for p-Tau 217 protein, characterized in that: include: 1) Pretreatment module: at least including the isotope peptide segment and sample diluent as shown in Seq No. 1, the formula sample of the isotope peptide segment is: 5-50fmol / L isotope peptide segment aqueous solution; the sample diluent includes: NP 40 with a mass fraction of 0.1%-1%, Tween 20 with a mass fraction of 0.1%-1%, Tris-HCl with a concentration of 20-80mM, NaCl with a concentration of 30-80mM, protease inhibitor with a mass fraction of 0.02%-0.2%, and phosphatase inhibitor with a mass fraction of 0.02%-0.2%; 2) Immune enrichment module: at least including nanomagnetic microsphere-antibody complex; 3) Cleaning the digestion module: at least a PBS solution containing 0.1% to 0.5% NP40 by mass and a 20-200 mM NH4HCO3 solution; 4) Desalination module: at least including methanol, 80% by mass acetonitrile aqueous solution, 1% by mass formic acid aqueous solution, and 80% by mass acetonitrile aqueous solution; 5) Drying and sampling module: at least 0.1% by mass of formic acid water.
10. Use of the detection kit for p-Tau 217 protein as claimed in claim 9 in the early diagnosis of Alzheimer's disease.
Citation Information
Patent Citations
Methods for measuring concentrations of biomolecules
US20160238619A1
Methods and compositions for tauopathy diagnosis and treatment
US20190234966A1
Anti-TAU MTBR antibodies and methods to detect cleaved fragments of TAU and uses thereof
WO2024044637A2
Method for diagnosing and / or classifying the severity of a neurodegenerative disease
WO2024133743A1
